2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
April 18th, 2025
Version: 1
Wellcome Sanger Institute
cancer biology
biorxiv

CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance

Watterson, A.Open in Google Scholar•Picco, G.Open in Google Scholar•Veninga, V.Open in Google Scholar•Samarakoon, Y.Open in Google Scholar•Cattaneo, C. M.Open in Google Scholar•Vieira, S. F.Open in Google Scholar•Karakoc, E.Open in Google Scholar•Bhosle, S.Open in Google Scholar•Battaglia, T. W.Open in Google Scholar•Consonni, S.Open in Google Scholaret al.

Cancer immunotherapy is only effective in a subset of patients, highlighting the need for effective biomarkers and combination therapies. Here we systematically identify genetic determinants of cancer cell sensitivity to anti-tumor immunity by performing whole-genome CRISPR/Cas9 knock-out screens in autologous tumoroid-T cell co-cultures, isogenic cancer cell models deficient in interferon signaling, and in the context of four cytokines. We discover that loss of CHD1 and MAP3K7 potentiates the transcriptional response to IFN-{gamma}, thereby creating an acquired vulnerability through sensitizing cancer cells to tumor-reactive T cells. Immune checkpoint blockade was more effective in a syngeneic mouse model of melanoma deficient in Chd1 and Map3k7 and was associated with elevated intra-tumoral CD8+ T cell numbers and activation. CHD1 and MAP3K7 are recurrently mutated in cancer and reduced expression in tumors correlates with response to immune checkpoint inhibitors in patients, nominating these genes as potential biomarkers of immunotherapy response.

Similar Papers

biorxiv
Fri Apr 18 2025
High-Dimensional Protein Analysis Uncovers Distinct Immunological and Stromal Signatures Between Primary and Metastatic Pancreatic Ductal Adenocarcinoma
Our understanding of the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME) primarily stems from murine models or primary patient tumors. While metastatic tumors have generally less immune infiltration compared to primary tumors, the specific cellular features of metastatic PDAC remain understudied. This knowledge gap is impactful as most patients present with metastatic disease ...
Greene, E.
•
Horvat, N. K.
•
Doxie, D. B.
•
Parihar, V. C.
...•
Lesinski, G. B.
biorxiv
Fri Apr 18 2025
A small molecule inhibitor of RNA-binding protein IGF2BP3 shows anti-leukemic activity
The RNA-binding protein IGF2BP3 is an oncofetal protein overexpressed in B-acute lymphoblastic leukemia and is critical for leukemogenesis in experimental models. With cancer-specific expression, functional dispensability for normal development, and an unleveraged pro-oncogenic function in mRNA homeostasis, IGF2BP3 represents an excellent target. With no small molecule inhibitors of IGF2BP3 in cli...
Rao, D. S.
•
Jaiswal, A. K.
•
Scherer, G. M.
•
Thaxton, M.
...•
Garg, N.
biorxiv
Fri Apr 18 2025
SKIDA1 transiently sustains MLL::ENL-Expressing hematopoietic progenitors during neonatal stages and promotes B-lineage priming
Infant leukemias arise as B-cell acute lymphocytic (B-ALL) or acute myeloid leukemia (AML). The majority are driven by chromosomal rearrangements of the MLL/ KMT2A gene (MLLr) and arise in utero, implying a fetal cell of origin. Fetal and neonatal hematopoietic progenitors have unique transcriptomes and epigenomes, raising the question of whether MLL fusion proteins activate distinct target gene p...
Mendoza-Castrejon, J.
•
Yang, W.
•
Denby, E.
•
Muthukumar, R.
...•
Magee, J. A.
biorxiv
Fri Apr 18 2025
CLM296: a highly selective inhibitor targeting ALDH1A3-driven tumor growth and metastasis in breast cancer
Aldehyde dehydrogenase 1A3 (ALDH1A3) increases tumor growth, metastasis, and chemoresistance in many solid tumors, including triple-negative breast cancer (TNBC), glioblastoma, melanoma, lung, and colon cancers, yet no clinically approved inhibitors exist. Here, we present CLM296, a novel and highly selective ALDH1A3 inhibitor designed to address this unmet need. CLM296 exhibits potent inhibition ...
MacLean, M. R.
•
Bernardoni, B. L.
•
Fernando, W.
•
Petrarolo, G.
...•
Marcato, P.
biorxiv
Fri Apr 18 2025
Transcriptional regulators FOXD1 and RBFOX2 contribute to metastatic capacity in BAP1mut uveal melanoma
Uveal melanoma is the most prevalent primary intraocular cancer, with a significant metastatic risk. This risk is dependent on the genetic drivers. Secondary mutations in EIF1AX, SF3B1 and BAP1 correlate with clinical outcomes and are recognized for their distinct transcriptomic and epigenetic profiles. Previously, we identified 480 genes involved in the development of ocular melanocytes. Top rank...
Brosens, E.
•
Nguyen, J.
•
Konemann, N.
•
van den Bosch, T.
...•
van den Bosch, Q.
biorxiv
Fri Apr 18 2025
New Δ246p53 isoform responds to DNA damage to enhance p53 functions in senescence and tumour suppression
p53 is with little doubt one of the most powerful genes in our genome, as it makes growth vs arrest, repair vs replacement, metabolism vs anabolism, life vs death decisions in the cell. An alteration or malfunction in p53 may lead to cancer or premature ageing. So, it is not surprising that p53 is also one of the most complex and tightly regulated genes. p53 alone encodes for at least 10 RNA varia...
Parkar, S. N.
•
Ramalho, A. C.
•
Lopez-Iniesta, M. J.
•
Kimura, K.
...•
Candeias, M. M.
biorxiv
Fri Apr 18 2025
Chemical Probe Discovery for DEAD-box RNA Binding Protein DDX21 using Small Molecule Microarrays
The DEAD-box family of ATPases plays a critical role in nearly all stages of RNA metabolism, from transcription to degradation, and serves as a major regulator of biomolecular condensates. Dysregulation of DEAD-box proteins is well established in a variety of diseases, including cancer and neurodegenerative disorders, making them attractive therapeutic targets. However, their classification as \"u...
Calo, E.
•
Koehler, A. N.
•
Aiba, T.
biorxiv
Fri Apr 18 2025
Potentiation of EGFR mutant lung cancer treatment targeting replication stress.
Oncogene-targeted therapies against growth factor receptors are effective treatment options for driver mutation-positive non-small cell lung cancer (NSCLC). The third-generation EGFR-Tyrosine Kinase inhibitor (TKI) osimertinib, is a standard first-line therapy for patients with EGFR-mutated NSCLC cancer. Acquired resistance to osimertinib is a significant problem that limits survival. In addition ...
Bhowmick, R.
•
Turchi, J. J.
•
Jalal, S. I.
biorxiv
Fri Apr 18 2025
Oncogene Silencing via ecDNA Micronucleation
Extrachromosomal DNA (ecDNA) is a common source of oncogene amplification across many types of cancer. The non-Mendelian inheritance of ecDNA contributes to heterogeneous tumour genomes that rapidly evolve to resist treatment. Here, using single-cell and live-cell imaging, single-micronucleus sequencing, and computational modelling, we demonstrate that elevated levels of ecDNA predisposes cells to...
Brueckner, L.
•
Xu, R.
•
Tang, J.
•
Herrmann, A.
...•
Wer